<DOC>
	<DOCNO>NCT00507442</DOCNO>
	<brief_summary>The purpose Phase 1/2 study evaluate efficacy safety treatment VELCADE , dexamethasone , Revlimid® ( VDR ) well VELCADE , dexamethasone , cyclophosphamide , Revlimid ( VDCR ) patient multiple myeloma receive prior treatment . This study evaluate whether addition Revlimid VELCADE Dexamethasone increase complete response ( CR ) / good partial response ( VGPR ) rate .</brief_summary>
	<brief_title>Phase 1/2 Study VELCADE® Combination With Other Drugs Treat Previously Untreated Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Voluntary write informed consent Male female subject 18 year age old A Karnofsky Performance Status score ≥50 % ( Eastern Cooperative Oncology Group Performance Status score ≤2 ) Subjects must symptomatic myeloma asymptomatic myeloma myelomarelated organ damage Diagnosed Multiple myeloma Subjects must measurable disease require systemic therapy Subjects must treat previously systemic therapy multiple myeloma Two week must elapse since date last radiotherapy treatment Women childbearing potential must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior therapy repeat within 24 hour start study drug . They must commit continued abstinence heterosexual intercourse begin 2 acceptable method birth control ( 1 highly effective method 1 additional effective method ) use time , begin least 4 week initiation Revlimid treatment . Women must also agree ongoing pregnancy test Men must agree father child agree use latex condom therapy 4 week last dose study drug , even successful vasectomy , partner childbearing potential All subject must agree comply requirement RevAssistSM program History allergy study medication , analogue , excipients various formulation ≥Grade 2 peripheral neuropathy clinical examination Myocardial infarction within 6 month prior enrollment New York Heart Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia clinically significant conduction system abnormality . Female subject pregnant breastfeeding Clinically relevant active infection serious comorbid medical condition Any condition , include laboratory abnormality , opinion Investigator place subject unacceptable risk he/she participate study . This include limited serious medical psychiatric illness likely interfere participation clinical study Active prior malignancy diagnose treat within last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Treatment patient multiple myeloma</keyword>
	<keyword>receive prior treatment</keyword>
</DOC>